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Aims Coarctation of the aorta (CoA) accounts for 4–8% of congenital heart defects (CHDs) and confers substantial
morbidity despite treatment. It is increasingly recognized as a highly heritable condition. The aim of the study was




We performed a genome-wide association study of CoA among Icelanders (120 cases and 355 166 controls) based
on imputed variants identified through whole-genome sequencing. We found association with a rare (fre-
quency = 0.34%) missense mutation p.Arg721Trp in MYH6 (odds ratio = 44.2, P = 5.0 10-22), encoding the alpha-
heavy chain subunit of cardiac myosin, an essential sarcomere protein. Approximately 20% of individuals with CoA
in Iceland carry this mutation. We show that p.Arg721Trp also associates with other CHDs, in particular bicuspid
aortic valve. We have previously reported broad effects of p.Arg721Trp on cardiac electrical function and strong
association with sick sinus syndrome and atrial fibrillation.
...................................................................................................................................................................................................
Conclusion Through a population approach, we found that a rare missense mutation p.Arg721Trp in the sarcomere gene
MYH6 has a strong effect on the risk of CoA and explains a substantial fraction of the Icelanders with CoA. This is
the first mutation associated with non-familial or sporadic form of CoA at a population level. The p.Arg721Trp in
MYH6 causes a cardiac syndrome with highly variable expressivity and emphasizes the importance of sarcomere in-
tegrity for cardiac development and function.
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Coarctation of the aorta (CoA) is the most common birth defect of
the aorta with an incidence of about one per 2500 live births.1 It is
defined by local narrowing of the proximal descending aorta and/or
aortic arch, accompanied by bicuspid aortic valve (BAV) in more than
50% of cases and generally presenting as either neonatal heart failure
or hypertension later in life.2 Surgical or interventional treatment
considerably improves outcome but risk of premature cardiovascular
morbidity and mortality remains despite appropriate therapy.3
Coarctation of the aorta is primarily a non-familial or sporadic dis-
ease.4 However, it has been shown to cosegregate in families with
left-ventricular outflow tract obstruction (LVOTO) malformations, a
mechanistically defined subgroup of congenital heart defects (CHDs)
including CoA, BAV, congenital aortic stenosis, and hypoplastic left
heart syndrome (HLHS).5 As a group, the LVOTO malformations
are markedly heritable (0.71–0.90) and have a high relative risk for
first-degree relatives (36.9).6 In addition, around 15% of individuals
with CoA occur as part of a recognized genetic syndrome (e.g. 45, X,
or Turner).7
Not much is known about genetic causes of non-syndromic CoA.
Several studies have found mutations in families with LVOTO malfor-
mations and a few instances of sporadic CoA, both with and without
concomitant CHDs. The most strongly implicated gene is NOTCH1,8–10
encoding a transmembrane receptor that regulates cell fate during de-
velopment. Mutations in other genes, including MYH611,12 SMAD6,13
NKX2-5,14 and GATA5,15 have been found in one or few individuals with
CoA. The MYH6 mutations were found in two families, one with predis-
position to atrial septal defect (ASD)11 and the other to HLHS.12 Some
individuals in these families presented with CoA. In addition, knockout
in mice of several genes found within copy number variants in individ-
uals with CoA, including MCTP2,16 MATR3,17 and FOXC1,18 have re-




The CoA sample set included 120 Icelanders who received the discharge
diagnosis of CoA at Landspitali, The National University Hospital (LUH)
in Reykjavik, the only tertiary referral centre in Iceland, between 1984
and 2016. The individuals were diagnosed with CoA between the years
1950 and 2016, with most individuals (75%) diagnosed after 1990. The in-
dividuals diagnosed with CoA were identified either through diagnostic
codes of CoA (ICD-9 code 747.1, ICD-10 code Q25.1) registered be-
tween 1990 and 2016 or procedure codes of CoA (WHO codes 1-273,
5-369, 5-382, and 5-387, NOMESCO codes FDJ 00, FDJ 10, FDJ 20, FDJ
30, FDJ 42, and FDJ 96) registered between 1984 and 2016. The diag-
noses of CoA were confirmed and detailed phenotypic characteristics
(Supplementary material online, Table S1) established through review of
electronic and paper medical records at LUH. Coarctation of the aorta
was defined as a non-syndromic congenital narrowing of the aorta, the
diagnosis of which was confirmed by a cardiologist with echocardiog-
raphy and/or cardiac catheterization. The individuals used as controls in
the CoA GWAS analyses consisted of disease-free individuals randomly
drawn from the Icelandic genealogical database and individuals from
other genetic studies at deCODE.
In addition to CoA, we included in the study the following samples
from the deCODE phenotype database: BAV, ASD, ventricular septal de-
fect (VSD), patent ductus arteriosus (PDA), late onset aortic valve sten-
osis (AVS), sick sinus syndrome (SSS), atrial fibrillation (AF), heart failure
(HF), ischaemic stroke (IS), hypertension (HTN), coronary artery disease
(CAD), left atrial diameter (LAD), aortic root diameter (ARD), left ven-
tricular end-diastolic diameter (LVEDD), electrocardiogram (ECG) data,
thoracic aortic aneurysm, high-degree atrioventricular block, and hyper-
trophic cardiomyopathy (Supplementary material online, Supplementary
methods).
All DNA samples used in the study are part of deCODE’s biobank es-
tablished in 1996 and built up since then through various genetic studies
at deCODE.
The study was approved by the Icelandic Data Protection Authority
and the National Bioethics Committee of Iceland. Study approval
numbers were VSN-15-053, VSN-15-016, VSN-15-056, VSN-15-058,
VSN-15-114, VSN-15-057, and 10-009-S1. Written informed consent
was obtained from all study participants. The study complies with the
declaration of Helsinki.
Genotyping, whole-genome sequencing, and imputation
For chip genotyping, 151 677 samples were typed with the Illumina
HumanHap300, HumanCNV370, HumanHap610, HumanHap1M,
HumanHap660, Omni-1, Omni 2.5, or Omni Express bead chips at
deCODE. Long range phasing of all chip-genotyped individuals was per-
formed with methods previously described19,20 (Supplementary material
online, Supplementary methods).
The whole genomes of 15 220 Icelanders were sequenced using
Illumina technology to a median depth of 35X (Supplementary material
online, Supplementary methods). The sequence variants identified in the
15 220 sequenced Icelanders were then imputed into 151 677 Icelanders
who had been genotyped with various Illumina single nucleotide poly-
morphism chips and their genotypes phased using long-range phasing.19,20
The imputation of the sequence variants, identified thorough whole-
genome sequencing (WGS), into the chip typed long-range phased indi-
viduals was performed with the same model as used by IMPUTE.21 The
utilization of long-range phased haplotypes enables accurate imputation
of variants with frequency down to approximately 0.02% in this data set.
Using genealogic information on Icelanders from The Book of
Icelanders,22 the sequence variants were imputed into first and second-
degree relatives of chip genotyped individuals (genealogical imputation),23
to further increase the sample size for association analysis and to increase
the power to detect associations. We identified 32.5 million high quality
sequence variants (all with imputation information >0.8 that mapped to
build hg38) that were tested for association with CoA under the multi-
plicative model.
Association analysis
In the association analysis were 120 individuals diagnosed with CoA and
355 116 individuals as controls, all with imputed genotypes. The sequence
variants imputed were identified through WGS of 15 220 Icelanders
(n = 33 individuals with CoA and n = 15 187 individuals as controls). Of
the individuals diagnosed with CoA, 39 were chip typed and long-range
phased and of the individuals who were controls 140 661 were chip
typed and long-range phased. These were imputed with the same model
as used by IMPUTE. The remaining individuals (n = 81 CoA cases and
n = 214 412 controls), were not chip typed themselves but were first or
second degree relatives of the chip typed individuals and imputed using
genealogical imputation as described in Ref.23
To account for inflation in test statistics due to cryptic relatedness and
stratification, we applied the method of linkage disequilibrium score
































































regression24 (Supplementary material online, Supplementary methods).
The estimated correction factor was 1.04 for the multiplicative model of
the CoA association. To correct for multiple testing we used the
weighted Holm–Bonferroni method25 to allocate family wise error rate
of 0.05 equally between four annotation-based classes of sequence vari-
ants (Supplementary material online, Supplementary methods). When
testing the association of p.Arg721Trp with several other cardiac pheno-
types, the individuals that served as controls consisted of disease-free in-
dividuals randomly drawn from the Icelandic genealogical database and
individuals from other genetic studies at deCODE.
Phenotypic differences between carriers and
non-carriers of p.Arg721Trp
To analyse if CoA carriers of the p.Arg721Trp mutation differed clinically
from non-carrier individuals with CoA, we evaluated the frequencies of
various clinical characteristics in these two groups with CoA (see
Supplementary material online, Table S2). Fisher’s exact test was used to
test for significant difference in the mean frequency of the variants be-
tween non-carriers and carriers, and the odds ratio (OR) was calculated
as [pa/(1-pa)]/[pc/(1-pc)], where pa and pc are the mean frequencies of
the variants in non-carriers and carriers, respectively.
Results
A rare missense mutation in MYH6
associates with coarctation of the aorta
To search for sequence variants that associate with non-syndromic
CoA, we performed a GWAS including 120 Icelanders with CoA and
355 116 Icelanders who served as population controls. We observed
a genome-wide significant association with CoA at chromosome
14q11 (Figure 1), explained by a rare (allele frequency = 0.34%) mis-
sense mutation p.Arg721Trp (c.2161C>T) in MYH6, encoding the
alpha myosin heavy chain subunit (aMHC) in cardiac muscle. Alpha
myosin heavy chain subunit is a main component of the sarcomere,
the basic contractile unit of cardiac muscle.26 P.Arg721Trp associates
with CoA with an OR of 44.2 (95% confidence interval 20.5–95.5)
and P = 5.01 10-22 (genome-wide significance threshold for mis-
sense variants was set at 6.5 10-8, see Methods)27 (Figure 2,
Table 1). None of the genotyped individuals (N = 151 677) were
homozygous for the mutation, consistent with its low frequency (1.8
homozygotes expected under Hardy–Weinberg equilibrium). Since
we observed no homozygotes, we could not discriminate between
the dominant and the multiplicative modes of inheritance.
The p.Arg721Trp mutation is located in exon 18 (out of 39 exons)
of MYH6 and leads to an arginine to tryptophan alteration at amino
acid 721 (full-length protein 1939 amino acid) (see Supplementary
material online, Figure S1). It is located in the converter domain of
aMHC (see Supplementary material online, Figure S1 and S2), a small
domain crucial in conveying a conformational change from the active
site to the lever arm upon adenosine triphosphate (ATP) hydroly-
sis.28 It is considered likely that the mutation alters protein function
(SIFT = 0, PolyPhen = 0.99, MutationTaster = 0.93), probably by alter-
ing the folding of the converter domain.
There were 987 carriers of p.Arg721Trp among the 151 677 chip-
typed Icelanders and eight of those (one per 123 carriers) were diag-
nosed with CoA. In line with low penetrance of the mutation for
CoA, p.Arg721Trp carriers diagnosed with CoA did not cluster in
families. However, 20% of the 39 chip-typed individuals with CoA
carried p.Arg721Trp. Thus, while the penetrance of the mutation for
CoA is low, it accounts for a large proportion of individuals with
CoA in the Icelandic population.
The p.Arg721Trp mutation is not present in the Exome Variant
Server, containing sequence data from 6503 individuals [Exome
Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle,
WA, USA] (http://evs.gs.washington.edu/EVS/) (August 2016) and
one copy was found in The Genome Aggregation Database
(gnomAD), holding data from 126 216 exome sequences and 15 136
WGS unrelated individuals.29 The p.Arg721Trp mutation thus ap-
pears to be absent from or present at a very low frequency in other
populations.
We show the phenotypic characteristics of individuals with CoA in
Supplementary material online, Table S1. About half were diagnosed
Figure 1 Manhattan plot of coarctation of the aorta genome-wide association study in Iceland. The P values (-log10) are plotted against their
respective positions on each chromosome.
















































.during the first month of life and three quarters during the first year
of life. As expected,3 CoA was more common in males than in fe-
males (1.6:1). About three quarters of individuals with CoA had other
CHDs, most commonly BAV and VSD. Similar to other studies,30 the
aortic valve was bicuspid in about half of those with CoA.
To determine whether there are phenotypic differences between
carriers (n = 24) and non-carriers (n = 96) of the p.Arg721Trp muta-
tion within the CoA sample set, we evaluated the frequencies of vari-
ous clinical characteristics in the two groups (see Supplementary
material online, Table S2). Carriers were nominally more likely to
present with mild rather than more critical and complex forms of
CoA (OR = 4.2 and P = 0.023). We observed no other differences.
Association of p.Arg721Trp in MYH6 with
other cardiac diseases
We have previously demonstrated that p.Arg721Trp associates
strongly with SSS and AF, atrial arrhythmias that are common in the
elderly and frequently coexist.31 With larger sample sizes, these asso-
ciations have become stronger; however, previously reported associ-
ation with thoracic aortic aneurysm is no longer significant (Table 1).
In the context of assessing effects of AF risk variants on cardiac con-
duction, we have also recently shown that p.Arg721Trp associates
with many ECG measures corresponding to a widespread effect on
electrical function of the heart32 (see Supplementary material online,
Figure S3).
To further explore the effect of the p.Arg721Trp MYH6 mutation,
we tested it for association with additional cardiac phenotypes,
including other CHDs, common heart diseases, and several echocar-
diogram variables (Table 1, Supplementary material online, Table S3
and Figure S3; significance threshold set at P < 0.003 (0.05/17 individ-
ual phenotypes tested). The p.Arg721Trp mutation associates with
increased risk of several CHDs: BAV, VSD, ASD, and PDA (Table 1).
As expected, the strongest association was with BAV (OR = 10.5 and
P = 7.3 10-8). In addition, the mutation associates with late onset
AVS. To assess if p.Arg721Trp associates with CHDs in the absence
of diagnosed CoA, we re-tested for association after removing indi-
viduals with CoA from the analysis. Although the effect of
p.Arg721Trp is consistently weaker, the associations remain (see
Supplementary material online, Table S3). We cannot exclude the
existence of undiagnosed CoA in these individuals. The mutation also
associates with HF and IS and with LAD but not with other variables
derived from the echocardiographic data such as ARD or LVEDD
(Table 1). The p.Arg721Trp mutation did not associate with
HTN or CAD.
Discussion
Through GWAS based on variants identified through WGS, we
found a rare missense variant in the sarcomere gene MYH6 that has a
strong effect on the risk of CoA in the Icelandic population and ex-
plains a substantial fraction of CoA in Icelanders. The same mutation
Figure 2 Region plot for the association of variants on 14q11 with coarctation of the aorta. Shown is a 1 Mb region on chromosome 14. The stron-
gest association is with the missense variant p.Arg721Trp in MYH6 located at position 23 396 970 on chromosome 14 (chr14: 23 396 970). The nine
other variants shown are weakly correlated with p.Arg721Trp, r2 between 0.6–0.4 (green) and 0.4–0.2 (light blue).
















































..also associates with other CHDs, in particular BAV. It has a wide-
spread effect on cardiac electrical function and associates strongly
with atrial arrhythmias, both SSS and AF. This is the first mutation
shown to associate with non-familial or sporadic form of CoA at a
population level. The p.Arg721Trp mutation appears to be absent
from other populations or if present, at a very low frequency. The
Icelandic population is a founder population in that a small number of
ancestors account for a relatively large proportion of genetic diver-
sity in the current population. Hence, sequence variants that are very
rare in more outbred populations, like p.Arg721Trp, may thus be
more frequent in Icelanders.33
Myosin is a major component of the sarcomere, the building block
of the contractile system of cardiac muscle. Myosin is an ATPase cel-
lular motor protein composed of two heavy chains and two pairs of
light chains. The two heavy chains are aMHC and beta myosin heavy
chain (bMHC) encoded by MYH6 and MYH7, respectively. Both
aMHC and bMHC are expressed throughout the heart during em-
bryonic cardiogenesis and bMHC continues to do so in the adult
heart whereas aMHC expression becomes restricted to the
atrium.34 Expression of MYH6 has not been detected in the aorta.35
The pathogenesis of CoA is not well understood. One of the main
models of CoA pathogenesis, the haemodynamic theory,2,36 main-
tains that cardiac lesions resulting in decreased left ventricular out-
flow promote development of CoA by reducing blood flow through
the Foetal aorta. The p.Arg721Trp mutation could predispose to
CoA by reducing blood flow through the Foetal aorta because of di-
minished contraction of the developing heart. This hypothesis is
supported by overexpression studies in rat cardiomyocytes showing
that the p.Arg721Trp mutation impairs sarcomeric structure37 and
by our ECG data demonstrating widespread effect of p.Arg721Trp
on cardiac electrical function, including in the ventricles. Our hypoth-
esis is compatible with the fact that MYH6 is expressed in the ven-
tricles during the development of the heart but not in the aorta.
Very rare mutations in MYH6, other than p.Arg721Trp, have been
linked to various CHDs,11,12,38 particularly familial ASD39,40 and both
dilated and hypertrophic cardiomyopathy.41 In all instances, these
mutations have been restricted to a few sporadic cases or too few
families. In two of these families, one with predisposition to ASD11
and the other to HLHS,12 some of the affected family members had
other cardiac defects, including CoA. p.Arg721Trp in MYH6 differs
from these rare familial mutations in that it associates with CoA at
the population level and explains about 20% of individuals with CoA
in Iceland.
The main limitation of the study is the small size of the CoA sample
set. A larger set might have facilitated detection of more variants
associating with CoA with weaker effects than observed for
p.Arg721Trp, and allowed a better estimate of the effect (OR), pene-
trance and the fraction of CoA cases explained by the mutation.
Conclusion
In conclusion, our findings give insights into the pathophysiology of
CoA, supporting the haemodynamic theory of the pathogenesis.
....................................................................................................................................................................................................................
Table 1 Association of p.Arg721Trp with congenital heart defects and various cardiac phenotypes
Naff Ncontr OR/effect (95% CI)
a P-value
Congenital heart defects
Coarctation of the aorta 120 355 116 44.2 (20.5 to 95.5) 5.0 10-22
Bicuspid aortic valve 208 293 346 10.5 (2.6 to 38.0) 7.3 10-8
Ventricular septal defect 715 357 641 4.4 (1.9 to 10.0) 3.7 10-4
Patent ductus arteriosus 594 357 762 4.9 (2.1 to 11.6) 2.3 10-4
Atrial septal defect 657 353 096 3.3 (1.5 to 7.1) 0.0026
Cardiac conditions
Sick sinus syndrome 3310 346 082 8.7 (6.8 to 11.2) 6.2 10-64
Atrial fibrillation 13 471 374 939 2.4 (1.9 to 3.0) 1.1 10-14
Aortic valve stenosis 2457 349 342 2.7 (1.8 to 4.0) 1.8 10-6
Heart failure 10 480 353 508 1.8 (1.4 to 2.3) 2.3 10-6
Ischaemic stroke 8948 369 624 1.5 (1.1 to 2.0) 0.0029
High degree atrioventricular block 1303 361 919 2.1 (1.2 to 3.5) 0.0092
Coronary artery disease 37 782 318 845 1.2 (1.0 to 1.5) 0.056
Hypertrophic cardiomyopathy 163 239 293 0.0 (0.0 to 4.5) 0.15
Thoracic aortic aneurysm 353 302 458 1.8 (0.6 to 5.3) 0.31
Hypertension 54 974 324 803 1.1 (0.9 to 1.3) 0.44
Echocardiogram
Left atrial diameter 19 380 0.3 (0.1 to 0.5) 2.6 10-4
Aortic root diameter 19 506 -0.1 (-0.2 to 0.1) 0.41
LVEDDb 5701 0.0 (-0.3 to 0.3) 0.93
Shown are the number of affected individuals and control individuals used in the association analysis for each of the traits.
aEstimated odds ratio (OR) or the effect in standard deviation and the 95% confidence interval (CI) for the association with p.Arg721Trp.
bLeft ventricular end-diastolic diameter.































































































Moreover, the pleiotropic effect of p.Arg721Trp in MYH6 suggests it
causes a cardiac syndrome with highly variable expressivity that is dif-
ficult to understand clinically without sequence information.
Furthermore, these data emphasize the importance of sarcomere in-
tegrity for cardiac development and function.
Supplementary material
Supplementary material is available at European Heart Journal online.
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